Your browser doesn't support javascript.
loading
Pulmonary hypertension associated with neurofibromatosis type 1.
Jutant, Etienne-Marie; Girerd, Barbara; Jaïs, Xavier; Savale, Laurent; O'Connell, Caroline; Perros, Frederic; Sitbon, Olivier; Humbert, Marc; Montani, David.
Affiliation
  • Jutant EM; Université Paris-Sud, Faculté de Médecine, Paris, France.
  • Girerd B; AP-HP, Centre de Référence de l'Hypertension Pulmonaire Sévère, Dépt Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO), Service de Pneumologie, Hôpital de Bicêtre, Paris, France.
  • Jaïs X; UMR_S 999, Univ. Paris-Sud, INSERM, Laboratoire d'Excellence (LabEx) en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Hôpital Marie-Lannelongue, Paris, France.
  • Savale L; Université Paris-Sud, Faculté de Médecine, Paris, France.
  • O'Connell C; AP-HP, Centre de Référence de l'Hypertension Pulmonaire Sévère, Dépt Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO), Service de Pneumologie, Hôpital de Bicêtre, Paris, France.
  • Perros F; UMR_S 999, Univ. Paris-Sud, INSERM, Laboratoire d'Excellence (LabEx) en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Hôpital Marie-Lannelongue, Paris, France.
  • Sitbon O; Université Paris-Sud, Faculté de Médecine, Paris, France.
  • Humbert M; AP-HP, Centre de Référence de l'Hypertension Pulmonaire Sévère, Dépt Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO), Service de Pneumologie, Hôpital de Bicêtre, Paris, France.
  • Montani D; UMR_S 999, Univ. Paris-Sud, INSERM, Laboratoire d'Excellence (LabEx) en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Hôpital Marie-Lannelongue, Paris, France.
Eur Respir Rev ; 27(149)2018 Sep 30.
Article in En | MEDLINE | ID: mdl-30158278
ABSTRACT
Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a frequent autosomal dominant genetic disorder with a prevalence of 1 in 3000. Pulmonary hypertension (PH) associated with NF1 (PH-NF1) is a rare but severe complication of NF1 and is classified as Group 5 PH, defined as "PH with unclear and/or multifactorial mechanisms". A literature review in PubMed on the association between NF1 and PH identified 18 articles describing 31 cases. PH-NF1 was characterised by a female predominance, an advanced age at diagnosis, an association with parenchymal lung disease in two out of three cases and poor long-term prognosis. NF1 is generally associated with interstitial lung disease but some cases of severe PH without parenchymal lung disease suggest that there could be a specific pulmonary vascular disease. There is no data available on the efficacy of specific pulmonary arterial hypertension treatment in PH-NF1. Therefore, these patients should be evaluated in expert PH centres and referred for lung transplantation at an early stage. As these patients have an increased risk of malignancy, careful assessment of the post-transplant malignancy risk prior to listing for transplantation is necessary. Clinical trials are needed to evaluate promising treatments targeting the RAS-downstream signalling pathways.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurofibromatosis 1 / Hypertension, Pulmonary Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur Respir Rev Year: 2018 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurofibromatosis 1 / Hypertension, Pulmonary Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur Respir Rev Year: 2018 Document type: Article Affiliation country: France
...